Angiotech Pharmaceuticals Inc. (ANPI, ANP.TO) said that its corporate partner, Boston Scientific (BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention using the Taxus Express Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft surgery.
The overall results demonstrated no statistically significant difference between PCI and CABG in the composite safety endpoint.
For comments and feedback: editorial@rttnews.com